UK markets closed

Keros Therapeutics, Inc. (KROS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
61.13+0.56 (+0.92%)
As of 02:59PM EDT. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
151
151
0
20,100
0
Operating expenses
Research development
135,258
135,258
87,265
55,143
33,860
Selling general and administrative
34,834
34,834
27,525
21,330
12,797
Total operating expenses
167,692
167,692
107,709
76,473
44,197
Operating income or loss
-167,541
-167,541
-107,709
-56,373
-44,197
Interest expense
0
0
1
4
6
Total other income/expenses net
14,549
14,549
3,031
-356
-1,330
Income before tax
-152,992
-152,992
-104,679
-56,733
-45,533
Income tax expense
0
0
0
2,011
-172
Income from continuing operations
-152,992
-152,992
-104,679
-58,744
-45,361
Net income
-152,992
-152,992
-104,679
-58,744
-45,361
Net income available to common shareholders
-152,992
-152,992
-104,679
-58,744
-45,361
Basic EPS
-4.96
-
-4.15
-2.52
-2.93
Diluted EPS
-4.96
-
-4.15
-2.52
-2.93
Basic average shares
28,751
-
25,241
23,334
15,506
Diluted average shares
28,751
-
25,241
23,334
15,506